Hypothesizing that sustained PLK1 inhibition is essential but additional targets are needed for effective targeting of KRAS‐mutant cancers, we undertook a chemical synthetic lethal screen for small‐molecule compounds that were able to enhance anti‐proliferative effects of BI2536, a selective and clinically advanced PLK1 inhibitor (Sebastian et al, 2010). This evidence concerns the gene KRAS and cancer.